# Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone

> **NCT03116295** · PHASE1 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 56 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Opicapone (OPC)

## Key facts

- **NCT ID:** NCT03116295
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-20
- **Primary completion:** 2017-08-28
- **Final completion:** 2017-08-28
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2018-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03116295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03116295, "Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03116295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*